Literature DB >> 31577058

Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.

Nicola R Jones1, Marian Shanahan1, Timothy Dobbins1, Louisa Degenhardt1, Mark Montebello1,2, Natasa Gisev1, Sarah Larney1.   

Abstract

INTRODUCTION AND AIMS: It is not known if the reduction in ED use during periods of OAT occurs across urgent and low acuity presentations. We aimed to compare the incidence and costs of urgent and low acuity ED presentations of people with opioid use disorder (OUD) in and out of opioid agonist treatment (OAT). DESIGN AND METHODS: This was a retrospective cohort study (N=24,875), using linked administrative health data from New South Wales (NSW), Australia. Urgent and low acuity ED incidence and associated costs were calculated for periods in and out of OAT. GEE models estimated the adjusted incidence rate ratio (IRR) for ED presentations. Average costs per person-day were calculated with bootstrap confidence intervals.
RESULTS: Incidence of urgent presentations was lower in OAT compared to out of OAT [IRR (95%CI): 0.65 (0.61-0.69)]. In major cities, low acuity presentations were lower during OAT compared to timeout of OAT [IRR (95%CI): 0.82 (0.70-0.96)], in regional/remote areas, low acuity presentations were higher during OAT [IRR (95%CI): 2.65 (1.66-4.21)]. In major cities, average costs for low acuity presentations in OAT were 28% lower atA$0.50 (95%CI: A$0.48-A$0.52) and A$0.69 (95%CI: A$0.66-A$0.71) out of OAT, but 103% higher in regional/remote NSW, at A$2.12 (95%CI: A$1.91-A$2.34) in OAT and A$1.04 (95%CI: A$0.91-A$1.16) out of OAT. DISCUSSION AND
CONCLUSIONS: OAT was associated with reductions in urgent ED presentations and associated costs among people with OUD. Geographical variation was evident for low acuity ED presentations, highlighting the need to increase access to OAT in regional/remote areas.
© 2019 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  buprenorphine; emergency medical services; health services geographic accessibility; methadone; opiate substitution treatment

Mesh:

Substances:

Year:  2019        PMID: 31577058      PMCID: PMC6777861          DOI: 10.1111/dar.12976

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  18 in total

Review 1.  The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature.

Authors:  M Mofizul Islam; Libby Topp; Carolyn A Day; Angela Dawson; Katherine M Conigrave
Journal:  Int J Drug Policy       Date:  2011-10-12

2.  Understanding drivers of Demand for Emergency Service Trends in Years 2010-2014 in New South Wales: An initial overview of the DESTINY project.

Authors:  Michael M Dinh; Saartje Berendsen Russell; Kendall J Bein; Dane Chalkley; David Muscatello; Richard Paoloni; Rebecca Ivers
Journal:  Emerg Med Australas       Date:  2016-02-03       Impact factor: 2.151

3.  Low acuity and general practice-type presentations to emergency departments: a rural perspective.

Authors:  Penny Allen; Colleen Cheek; Simon Foster; Marielle Ruigrok; Deborah Wilson; Lizzi Shires
Journal:  Emerg Med Australas       Date:  2015-02-26       Impact factor: 2.151

4.  Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence.

Authors:  Ryan Schwarz; Alexei Zelenev; R Douglas Bruce; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2012-04-24

5.  Harm minimization strategies: opinions of health professionals in rural and remote Australia.

Authors:  G M Peterson; S Northeast; S L Jackson; K D Fitzmaurice
Journal:  J Clin Pharm Ther       Date:  2007-10       Impact factor: 2.512

Review 6.  Unobserved "home" induction onto buprenorphine.

Authors:  Joshua D Lee; Frank Vocci; David A Fiellin
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

7.  Are People Who Inject Drugs Frequent Users of Emergency Department Services? A Cohort Study (2008-2013).

Authors:  Dhanya Nambiar; Tim Spelman; Mark Stoové; Paul Dietze
Journal:  Subst Use Misuse       Date:  2017-10-16       Impact factor: 2.164

8.  Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study.

Authors:  Sarah Larney; Jason Grebely; Michael Falster; Alexander Swart; Janaki Amin; Louisa Degenhardt; Lucinda Burns; Claire M Vajdic
Journal:  Drug Alcohol Depend       Date:  2015-01-05       Impact factor: 4.492

9.  Frequent emergency department presentations among people who inject drugs: A record linkage study.

Authors:  Dhanya Nambiar; Mark Stoové; Paul Dietze
Journal:  Int J Drug Policy       Date:  2017-05-13

10.  Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont.

Authors:  Mary Kate Mohlman; Beth Tanzman; Karl Finison; Melanie Pinette; Craig Jones
Journal:  J Subst Abuse Treat       Date:  2016-05-09
View more
  4 in total

1.  Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.

Authors:  Sarah Larney; Nicola Jones; David A Fiellin; Suzanne Nielsen; Matthew Hickman; Timothy Dobbins; Thomas Murphy; Robert Ali; Louisa Degenhardt
Journal:  Int J Epidemiol       Date:  2021-01-23       Impact factor: 7.196

2.  Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia.

Authors:  Thomas D Brothers; Dan Lewer; Nicola Jones; Samantha Colledge-Frisby; Michael Farrell; Matthew Hickman; Duncan Webster; Andrew Hayward; Louisa Degenhardt
Journal:  PLoS Med       Date:  2022-07-19       Impact factor: 11.613

Review 3.  Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.

Authors:  Em M Pijl; Abeer Alraja; Elsie Duff; Carol Cooke; Stephen Dash; Nichole Nayak; Jesse Lamoureux; Ginette Poulin; Erin Knight; Ben Fry
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-08-26

4.  Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.

Authors:  Nicola R Jones; Suzanne Nielsen; Michael Farrell; Robert Ali; Anthony Gill; Sarah Larney; Louisa Degenhardt
Journal:  Drug Alcohol Depend       Date:  2020-12-19       Impact factor: 4.492

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.